Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies
Disclosure Date:
6/4/2013
Combined Therapeutic Method for Solid Tumor JHU REF: [C12570] Invention novelty: This technology is a combination therapy method including a tumor-specific bacterium and antibodies that boost tumor immune response. Value Proposition Worldwide cancer affects more than 12 million people each year. This number is expected to increase to 14 million each year by 2015. Solid tumors generally contain hypoxic tumor cores where a few live tumor cells reside in a quiescent state. These core residing tumor cells are often resistant to standard treatments (e.g. radiotherapy and chemotherapy), survive initial treatment, and become a source for tumor recurrence and metastasis. This technology overcomes the challenge of destroying core residing tumor cells by combining the intravenous injection of a lytic tumor-specific bacterium with two antibodies that target immune cell surface receptors, eliciting a powerful anti-tumor response. Advantages of this technology include: • Enhanced efficacy for treating solid tumors compared to either antibody or lytic bacterium treatment alone • Reduced chance of cancer recurrence and increased patient survival and quality of life • Targeted therapy that specifically affects tumor cells, while healthy cells are unaffected Technical Details Johns Hopkins researchers have developed a combination therapeutic method for solid tumors. An attenuated anaerobic tumor core-targeting bacterial strain combined with anti-CTLA-4 and anti-PD-1 antibodies can effectively treat solid tumors. In a metastatic murine tumor model (4T1), the number of metastases was markedly reduced leading to significant survival benefit following a combination of tumor-lytic bacteria (intravenously injected) and CTLA-4 and PD-1 antibodies (intraperitoneally injected). This method can be further developed into a therapeutic intervention for human patients with solid metastatic tumors. Looking for Partners: To develop & commercialize the technology as a therapeutic method for solid tumors. Stage of Development: Pre-clinical Data Availability: Under CDA/NDA Patent Status: Pending Publication(s)/Associated Cases: Not at this time Categories: Therapeutics Keywords: solid tumor, cancer, anaerobic bacteria, anti-CTLA-4, anti-PD-1, combination therapy.
Patent Information:
| Title |
App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Expire Date |
Patent Status |
| Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies |
PCT: Patent Cooperation Treaty |
Australia |
2015240884 |
2015240884 |
3/31/2015 |
10/1/2020 |
3/31/2035 |
Granted |
| Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies |
PCT: Patent Cooperation Treaty |
Mexico |
MX/a/2016/012891 |
378397 |
3/31/2015 |
12/16/2020 |
3/31/2035 |
Granted |
| Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies |
DIV: Divisional |
Japan |
2020-58163 |
7001731 |
3/31/2015 |
12/28/2021 |
3/31/2035 |
Granted |
| Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies |
DIV: Divisional |
Japan |
2021-210353 |
7240685 |
3/31/2015 |
3/8/2023 |
3/31/2035 |
Granted |
| Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies |
DIV: Divisional |
Australia |
2020230294 |
2020230294 |
3/31/2015 |
6/8/2023 |
3/31/2035 |
Granted |
| Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies |
DIV: Divisional |
Japan |
2023-27184 |
7431409 |
3/31/2015 |
2/6/2024 |
3/31/2035 |
Granted |
| Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies |
DIV: Divisional |
Australia |
2023202788 |
|
3/31/2015 |
|
|
Pending |
| Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies |
DIV: Divisional |
Japan |
2024-008618 |
|
3/31/2015 |
|
|
Pending |
| Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies |
PCT: Patent Cooperation Treaty |
Japan |
2016-559826 |
6712952 |
3/31/2015 |
6/4/2020 |
3/31/2035 |
Granted |
| Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies |
PCT: Patent Cooperation Treaty |
European Patent Office |
15773992.1 |
|
3/31/2015 |
|
|
Pending |
| Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies |
PCT: Patent Cooperation Treaty |
Canada |
2,944,456 |
2,944,456 |
3/31/2015 |
10/31/2023 |
3/31/2035 |
Granted |
| Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies |
PCT: Patent Cooperation Treaty |
United States |
15/301,163 |
|
9/30/2016 |
|
|
Pending |
|
|
Inventors:
Category(s):
Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Immunotherapies,
Get custom alerts for techs in these categories/from these inventors:
|
